Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin in liver transplant candidates with anemia
2025-521701-41-00Phase 4Authorised
- Sponsor
- IDIBAPS
- Start
- Nov 2025
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of darbepoetin alfa in anaemia and hepatic disease (2 arms), sponsored by IDIBAPS. Primary endpoint: Intraoperative red blood cell transfusion rate. Planned start Nov 2025; status: authorised.
02
Drugs
darbepoetin alfa
03
Conditions
anaemiahepatic disease
Beyond the preview
Go deeper on 2025-521701-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521701-41-00.